Vier rechters die het niet eens zijn met CAFC-ontkenning van repetitie in generieke artrose-medicijnzaak

Vier rechters die het niet eens zijn met CAFC-ontkenning van repetitie in generieke artrose-medicijnzaak

maart 24, 2020 0 Door admin

Translating…


CBD Olie kan helpen bij artrose. Lees hoe op MHBioShop.com


Huile de CBD peut aider avec l’arthrose. Visite HuileCBD.be


 

“Advantages of an invention recited in the specification or in the prosecution history, but not in the claims, are not part of the claims…. The advantages of an invention and disclosure of how to make and use an invention are not to be incorporated into claims for purposes of evaluating their indefiniteness.” – CAFC Judge Lourie dissent

denied - https://depositphotos.com/4540592/stock-photo-denied-rubber-stamp.htmlThe U.S. Court of Appeals for the Federal Circuit (CAFC) today denied HZNP Medicines LLC’s (Horizon’s) request for rehearing in HZNP Medicines LLC v. Actavis Laboratories UT, Inc., with Judges Newman, O’Malley, Stoll and Lourie dissenting. Judge Lourie, writing for the dissent, said that the Court “has erroneously misconstrued the ‘consisting essentially of’ language in evaluating the definiteness requirement of 35 U.S.C. § 112” and that rehearing en banc should have been granted.

In October, the CAFC affirmed the U.S. District Court for the District of New Jersey’s findings of invalidity and noninfringement of certain claims of some of the asserted Horizon patents, as well as the district court’s finding of nonobviousness of one claim of another Horizon patent. Judge Newman dissented in that decision, saying that “The majority’s new ruling sows conflict and confusion” and that it could “cast countless patents into uncertainty.”

The October decision meant that  Actavis, owned by generic drug maker Teva Pharmaceuticals, was enjoined from engaging in the commercial use, offer for sale, or sale of its product covered in its Abbreviated New Drug Application (ANDA) until the expiration of U.S. Patent No. 9,066,913 (the ‘913 patent) in 2027.

In its analysis, the CAFC addressed the district court’s ruling of indefiniteness of Horizon’s claims. Under Nautilus, Inc. v. Biosig Instruments, Inc., the Supreme Court determined that a claim is invalid for indefiniteness if its language, read in light of the specification and prosecution history, fails to reasonably inform those skilled in the art about the scope of the invention.

[[Advertisement]]

In this case, the CAFC said in part that the phrase “consisting essentially of” referenced in Claim 49 of Horizon’s U.S. Patent No. 8,252,838, which demonstrates the use of the asserted claims of the formulation patent group, was indefinite because the patent listed two methods to achieve better drying time with inconsistent results, therefore preventing the POSITA from having reasonable certainty about the scope of the basic and novel properties of the invention, and thereby rendering the term “consisting essentially of” indefinite under the Nautilus standard.

The Court referenced PPG Industries and AK Steel in holding that courts evaluating claims that use the phrase “consisting essentially of” may ascertain the basic and novel properties of the invention at the claim construction stage, and then consider if the intrinsic evidence establishes what constitutes a material alteration of those properties. Therefore, if a POSITA cannot ascertain the bounds of the basic and novel properties of the invention, there is no basis upon which to ground the analysis of whether an unlisted ingredient has a material effect on the basic and novel properties.

In the dissent issued with today’s order, Judge Lourie wrote: “The majority here, affirming the district court, concluded that the claim was indefinite because of inconsistencies in the meaning of ‘better drying time.’ However, better drying time is not in the claim, and it is the claims that the statute requires be definite.”

He continued:

Aside from the specifics of “better drying time” in this case, the issue is of broader importance. Advantages of an invention recited in the specification or in the prosecution history, but not in the claims, are not part of the claims. Certainly the written description should be consulted to interpret claims, as they are drafted to be read together. See 35 U.S.C. § 112 (2010) (“The specification shall contain a written description of the invention . . . [and] shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.”). But the advantages of an invention and disclosure of how to make and use an invention are not to be incorporated into claims for purposes of evaluating their indefiniteness. It is the language of the claims that determines their definiteness.

Ultimately, said Lourie, “the principle of importing an uncertainty in measuring an advantage of an invention could have unintended potential effects well beyond this particular case. It should not be sound precedent.”

Image Source: Deposit Photos
Image ID: 4540592
Copyright: Rangizzz 

The Author

Warning & Disclaimer: The pages, articles and comments on IPWatchdog.com do not constitute legal advice, nor do they create any attorney-client relationship. The articles published express the personal opinion and views of the author and should not be attributed to the author’s employer, clients or the sponsors of IPWatchdog.com. Read more.

Discuss this

Lees Meer